Call Us: 1.800.873.5297


Recent Study Concludes that Users of Testosterone Supplements at Increased Risk of Heart Attack or Stroke

ABC News reported on a study published by the Journal of the American Medical Association (JAMA), which followed more than 8,000 male veterans with low testosterone. After comparing cardiovascular events in males taking a testosterone supplement with those who were not taking such supplements, the study concluded that men who used a supplement were 29% more likely to die, have a heart attack, or experience a stroke within three years of use. This was the result even after considering various factors that contribute to cardiovascular illnesses, such as age, blood pressure, and existing heart disease.

With an estimated 5.3 million prescriptions written by U.S. doctors each year, ABC News reports that the testosterone industry has seen more than a five-fold increase from 2000-2011. Dr. Steven Nissen, chairman of cardiovascular medicine at the Cleveland Clinic, told ABC News that he believes the growing number of men using testosterone supplements is largely due to the direct-to-consumer advertising. He recommends that the FDA require a large, randomized, controlled clinical trial to determine the safety of testosterone therapy. He added, “The widespread use of testosterone replacement in men is concerning, with no studies that show long-term safety.”

Testosterone therapy was approved by the FDA to treat abnormally low testosterone levels. However, some of the manufacturers of these products are promoting their use for conditions not necessarily related to low testosterone levels, such as energy loss, mood changes, and reduced sex drive among others. These conditions may not be related to low testosterone, but simply the aging process or improper diet and exercise. Because of these aggressive marketing strategies, the estimated sales of testosterone drugs are projected to reach $5 billion by 2017.

These testosterone supplement products include:

  • Androgel®
  • Androderm®
  • Fortestra®
  • Axiron®
  • Testim®
  • Bio-T-Gel®
  • Delatestryl®
  • Depo-Testosterone®
  • Striant®
  • Testopel®

The Pharmaceutical Litigation Department at Schlichter, Bogard & Denton, LLP represent clients nationwide who have suffered serious and fatal injuries as a result of dangerous pharmaceutical medications. At Schlichter, Bogard & Denton, LLP, we are committed to protecting the rights of persons injured by pharmaceutical companies.

The attorneys at Schlichter, Bogard & Denton, LLP are offering a free case review with no further obligation to those who have suffered injuries after using testosterone therapy. If you suffered injuries after using testosterone therapy, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.

The choice of a lawyer is an important decision and should not be based solely on advertisements.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.